Fu'an Pharmaceutical: Aztreonam for injection passed the consistency evaluation of generic drug quality and efficacy

Shanghai Securities News China Securities Network News (reporter Xia Zihang) Fu'an Pharmaceutical announced at noon on December 20 that the company's wholly-owned subsidiary Fu'an Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingyutang") recently received a notice of approval for the drug supplement application approved by the State Drug Administration, and its product axtronam for injection passed the consistency evaluation of the quality and efficacy of generic drugs.

According to reports, aztreonam for injection is mainly suitable for the treatment of infections caused by sensitive gram-negative bacteria, including urinary tract infections, lower respiratory tract infections, sepsis, skin and skin structure infections, intra-abdominal infections, gynecological infections, etc.

Fuan Pharmaceutical said that as of now, there are 65 domestic approvals for the above three specifications of this variety, involving 35 manufacturers. Qingyutang is the second manufacturer in China to pass the consistency evaluation. The consistency evaluation of the product will further enhance the technical level of the company's product and help improve the market competitiveness of the product.